Physician profile
Zinal Soni
NPI 1720342405
$668.69
in general payments reported to CMS, 2019-2025
11 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.47 · 2023: $160 · 2024: $212 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $242.69 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $138.97 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Lilly USA, LLC | $55.82 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $45.67 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.49 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $29.92 | 2023 | |
| Pfizer INC. | $29.44 | 2024 | |
| Novo Nordisk INC | $28.71 | 2023-2025 | Wegovy |
| Astellas Pharma US INC | $25.77 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.75 | 2023 | Xifaxan |
| Amgen INC. | $14.46 | 2024 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zinal Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.